Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 476Carcinoma, Hepatocellular 131Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 62Pancreatic Neoplasms 54Liver Neoplasms 44Stomach Neoplasms 37Neoplasms 37Esophageal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Colorectal Cancer Metastatic 19Ovarian Neoplasms 15Gastrointestinal Neoplasms 14Breast Neoplasms 13Biliary Tract Neoplasms 13Adenocarcinoma 11Lung Neoplasms 10Carcinoma, Renal Cell 10Digestive System Neoplasms 9Cholangiocarcinoma 9Intestinal Neoplasms 8Melanoma 7Gallbladder Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1Ipilimumab 1Interleukin-2 1IFL protocol 1HhAntag691 1Folfox protocol 1Capecitabine 1CTLA-4 Antigen 1Bevacizumab 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × Bevacizumab × Gastrointestinal × Clear all
NCT00959647 2026-05-08

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Genentech, Inc.

Phase 2 Completed
19 enrolled 10 charts
DermatologicGastrointestinalGynecologic

Carcinoma, Basal Cell, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡